Deep-Priming™ Technology Platform

Torque’s technology platform uses advanced cell process engineering to (a) prime and activate T cells to target multiple tumor antigens, and (b) tether immune-stimulatory drugs directly to the surface of these multi-target T cells to stimulate the immune response locally in the tumor microenvironment. These Deep-Primed T cells both target multiple tumor antigens, and pharmacologically activate an immune response with anchored cytokines. This process does not require genetic engineering of the T cells and so preserves the natural T cell receptor for delivering a regulated immune response, with the potential for a high margin of safety. We call this new class of immunotherapy “Deep-Primed T cells.”

Antigen priming of T cells to target multiple, tumor-associated antigens
Deep-Primed T cells are produced from the patient’s own immune cells, by priming their CD8 and CD4 cells to recognize multiple specific tumor-associated antigens. Current CAR T and TCR approaches target a single epitope of only one target antigen. In contrast, we use a process that enables multiple tumor-associated antigens that is modular, to allow use of different cassettes of antigens to target a wide range of tumors. This proprietary cell manufacturing process produces several billion tumor-targeted T cells.

Tethering powerful immunomodulators to the surface of T cells
In addition to antigen priming, we are tethering a focused set of immunomodulators to the surface of the T cells—initially IL-15, IL-12, and TLR agonists—for Deep-Priming that activates both innate and adaptive immunity. Administering these immunomodulators systemically to a patient can cause lethal toxicity by activating immune cells throughout the body. By loading precise doses of cytokines onto the surface of T cells, Deep-Priming focuses the immune response to target the tumor, without systemic exposure. These T cells traffic to the tumor with the cytokine, which is slowly released over 7-14 days to deliver a sustained and controlled immune activation in the tumor microenvironment, without systemic exposure.

Natural T Cell Receptors for Full Immune Signaling

Deep-Priming does not require genetic engineering of the T cells and so preserves the natural T cell receptor for delivering a regulated immune response, with the potential for a high margin of safety. Deep-Priming retains all the natural functions of natural T cells. including:

  • recognizing, trafficking, and killing cancer cells
  • integrating with the full immune system to drive antigen spreading and memory
  • regulating immune response as the immune system is designed to do
Fluorescence Microscopy Image of Deep-Primed T cells:
Torque Deep-Primed™ Immune Cell Therapeutics
Deep-Primed T Cells on the move:
This video shows Deep-Primed T cells migrating through a collagen matrix in cell culture. The blue flashlights visible on the tail of each cell are clustered immunomodulatory drugs carried by the T cell surface receptors. The biotherapeutic components have been moved to the rear of the cell, where the T cell carries those receptors.
A Deep-Primed T cell recognizes and infiltrates its target:
When the Deep-Primed T cell encounters a tumor cell (green), the cytokine (blue) on the T cell surface starts moving into the interface. The blue speckles show the early stages of the T cell moving the cluster of cytokines into the interface with the tumor cell, where the drug cross-linkers dissolve and release the drug in a controlled and measured process.
Back to Top